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It is unclear whether system factors
regulate human colonic stem cell (CoSC)
populations to control homeostasis of
colonic epithelium. Now, D’Addio et al.
demonstrate that circulating IGF-I/
IGFBP3 controls CoSCs and represent a
therapeutic target for restoring colonic
function in patients with intestinal
disorders arising from long-standing type
1 diabetes.
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The role of circulating factors in regulating colonic
stem cells (CoSCs) and colonic epithelial homeo-
stasis is unclear. Individuals with long-standing
type 1 diabetes (T1D) frequently have intestinal
symptoms, termed diabetic enteropathy (DE),
though its etiology is unknown. Here, we report
that T1D patients with DE exhibit abnormalities
in their intestinal mucosa and CoSCs, which fail
to generate in vitro mini-guts. Proteomic profiling
of T1D+DE patient serum revealed altered levels
of insulin-like growth factor 1 (IGF-I) and its bind-
ing protein 3 (IGFBP3). IGFBP3 prevented in vitro
growth of patient-derived organoids via binding
its receptor TMEM219, in an IGF-I-independent
manner, and disrupted in vivo CoSC function in
a preclinical DE model. Restoration of normogly-
cemia in patients with long-standing T1D via
kidney-pancreas transplantation or in diabetic
mice by treatment with an ecto-TMEM219 re-
combinant protein normalized circulating IGF-I/
IGFBP3 levels and reestablished CoSC homeo-
stasis. These findings demonstrate that peripheral
IGF-I/IGFBP3 controls CoSCs and their dysfunc-
tion in DE.486 Cell Stem Cell 17, 486–498, October 1, 2015 ª2015 Elsevier Inc.INTRODUCTIONGastrointestinal disorders, consisting of gastroparesis, abdom-
inal distension, irritable bowel syndrome, and fecal incontinence,
are common in individuals with type 1 diabetes (T1D) (The Dia-
betes Control and Complications Trial Research Group, 1993).
Indeed, up to 80% of individuals with long-standing T1D, who
are generally affected by several diabetic complications
including end stage renal disease (ESRD) (The Diabetes Control
and Complications Trial Research Group, 1993; Atkinson et al.,
2014; Fiorina et al., 2001), show intestinal symptoms. The pres-
ence of these gastrointestinal symptoms, known as diabetic
enteropathy (DE), significantly reduces the quality of life (The
Diabetes Control and Complications Trial Research Group,
1993; Atkinson et al., 2014; Camilleri, 2007; Talley et al., 2001)
and has a largely unknown pathogenesis (Feldman and Schiller,
1983). Preclinical studies showed significant derangement of the
intestinal mucosa morphology in diabetic rodents (Dome`nech
et al., 2011; Zhao et al., 2003), suggesting that in T1D, intestinal
homeostasis may be altered; however, little data are available in
humans. The intestinal epithelium is maintained by intestinal
stem cells and their niche, which respond to physiological stress
and to environmental injury (Barker, 2014; Medema and Vermeu-
len, 2011). Colonic stem cells (CoSCs), located at the crypt base
of the large intestine and expressing the ephrin B receptor 2
(EphB2), leucine-rich repeat containing G protein-coupled
receptor 5 (LGR5), human telomerase reverse transcriptase
(h-TERT), and aldehyde dehydrogenase (Aldh), among other
markers (Carlone and Breault, 2012; Carpentino et al., 2009;
Jung et al., 2011; Sato and Clevers, 2013), constitute, together
with the local microenvironment, the CoSC niche (van der Flier
and Clevers, 2009; Zeki et al., 2011). Recent studies have estab-
lished conditions that recapitulate many features of intestinal
homeostasis and generate normal self-renewing crypt organoids
in vitro, or so-called ‘‘mini-guts’’ (Jung et al., 2011; Sato and
Clevers, 2013; Sato et al., 2011). Whether systemic factors,
such as circulating hormones, serve to control CoSCs remains
to be established (Stange and Clevers, 2013). We hypothesize
that a dyad consisting of a circulating enterotrophic regulating
factor and its binding protein (insulin-like growth factor 1 (IGF-I),
and its binding protein 3, IGFBP3) finely controls CoSCs and be-
comes dysfunctional in DE. Here we demonstrate that individuals
with long-standing T1D and DE have altered CoSCs and show
increased circulating levels of IGFBP3. Administration of IGFBP3
alters CoSC self-renewal potential and mucosal morphology
invitroand invivo, inapreclinicalmodel ofDE,byquenchingcircu-
lating IGF-I and by exerting a TMEM219-dependent/caspase-
mediated toxic effect on CoSCs. Finally, targeting IGFBP3 with
the newly generated ecto-TMEM219 recombinant protein, based
on the extracellular domain of the IGFBP3 receptor (TMEM219),
abrogates IGFBP3 deleterious effects in vitro and in vivo.
RESULTS
Intestinal Dysfunction and Clinical Symptoms
Are Present in Long-Standing T1D
We first characterized intestinal morphology and function in
a population of individuals with long-standing T1D and end stage
renal disease (T1D+ESRD) and in healthy subjects (CTRL).
Severe intestinal symptoms, such as diarrhea, abdominal pain,
and constipation were evident in T1D+ESRD individuals as
assessed using the Gastrointestinal Symptom Rating Scale
(GSRS) questionnaire (Figures 1A–1C). Symptoms were associ-
ated with abnormalities in anorectal sphincter function (Figures
1D–1F). The intestinal mucosa was altered in individuals with
T1D+ESRD as compared to healthy subjects, with lower
numbers of crypts, distortion, and zonal sclerosis of the lamina
propria (Figures 1G1–1H). A significant reduction in epithelial
cell proliferation as assessed by MKI67 (MIB1 antibody) staining
(Figures 1I1–1J), signs of neural degeneration, and reduction in
serotonin expression in intestinal neuroendocrine cells (Figures
1K–1N) were observed, confirming the presence of DE in these
individuals.
CoSCs Are Altered in Long-Standing T1D
The characterization of colonic crypts revealed a significant
reduction in EphB2+ expression and in the number of aldehyde
dehydrogenase (Aldh)+ immunoreactive cells, both markers of
local stem cells (Carpentino et al., 2009; Jung et al., 2011), in
T1D+ESRD individuals as compared to healthy subjects (Figures
1O–1R). A profound decrease was evident, upon gating on viable
cells at FACS analysis (Figures S1A–S1C), in the percentage of
EphB2hi, EphB2hi+LGR5+, and EphB2+h-TERT+ cells isolated
from intestinal crypts obtained from T1D+ESRD individuals as
compared to healthy subjects (Figures 2A–2E; Figures S1D and
S1E) andwasconfirmedbyRT-PCR (Figures 2F–2H) andwestern
blot (WB) analysis (Figure S1F). Transcriptome profiling of cryptsCeobtained from T1D+ESRD documented decreased expression in
Notch pathway (NOTCH1 and 2, JAG1, DLL1, and SOX1 and 2),
Wnt pathway (APC, FZD1, DKC1, ETS2, FAM84A, GPX2, and
RNF43), and BMP pathway (BMP1, BMP2, and BMP3) genes,
previously known pathways that control CoSCs, as compared
to the expression of these genes in healthy subjects (Figure S1G
and Table S1). Analysis of CoSC signature genes revealed that
LGR5, EPHB2 (Gracz et al., 2013; Merlos-Sua´rez et al., 2011),
h-TERT (Breault et al., 2008), and other intestinal stemcellmarker
genes (Hughes et al., 2011;Mun˜oz et al., 2012; Ziskin et al., 2013)
were significantly underexpressed in T1D+ESRDas compared to
healthy subjects as well (Figure 2I), confirming that CoSCs are
altered in individuals with DE.
In Vitro Generation of Mini-Guts Is Altered in
Long-Standing T1D
In order to evaluate CoSC self-renewal properties, we used the
in vitro mini-gut assay. Indeed, crypts isolated from T1D+ESRD
individuals and cultured in vitro for 8 days formed small spheroid
mini-guts that failed to grow as compared to those from healthy
subjects (Figures 2J1–2K), despite a comparable viability (Fig-
ures S1H and S1I) and efficiency of forming mini-guts in both
groups (Figure S1J). To begin to elucidate the effect of circulating
factors and high glucose on CoSCs, we cultured isolated intes-
tinal crypts (obtained from either healthy subjects or long-stand-
ing T1D individuals) in high glucose with/without serum in vitro
for 8 days (Figures 2L–2M). High glucose partially prevented
the generation of fully mature mini-guts and synergized with
serum of long-standing T1D individuals in altering CoSC self-
renewal properties, such that mini-guts appeared collapsed
(Figures 2L2–2L4). Analysis of gene expression also revealed
changes in the CoSC signature (Figure 2N), thus suggesting
that hyperglycemia and circulating factors act together to alter
CoSC self-renewal properties in long-standing T1D.
Serum Unbiased Proteomic Profiling Revealed
Increased Levels of IGFBP3 in Long-Standing T1D
In order to identify potential circulating factors that may serve
as enterotrophic hormones and may have a role in regulating
CoSCs, we compared the serum proteome of healthy subjects
with T1D+ESRD individuals using an unbiased proteomic
approach. A clear proteomic profile was evident in T1D+ESRD
individuals as compared to healthy subjects, with more than
50% of the detected proteins segregating in either one group
or the other (Figure 3A). Some proteins were associated with
diabetes, and some were growth factors or stem cell-related
proteins or were potentially involved in intestinal functions
(Figure 3A). In particular, the levels of IGF-I binding proteins
(IGFBP2 and 3) were detectable in long-standing T1D individuals
as compared to healthy subjects, with IGFBP3 almost 5-fold
increased (Figure 3B), while IGFBP1, 4, 5, and 6 remained almost
undetectable. Interestingly, in the liver of individuals with long-
standing T1D, hepatocytes, but not Kupffer cells, showed a
higher IGFBP3 immunohistochemical expression as compared
to healthy subjects (Figures 3C1 and 3C2; Figures S1K–S1L),
suggesting an increase in IGFBP3 hepatic synthesis and release.
The effect of high glucose on IGFBP3 hepatic release was
confirmed by the detection of increased IGFBP3 levels in the
supernatant of human immortalized hepatocytes exposed toll Stem Cell 17, 486–498, October 1, 2015 ª2015 Elsevier Inc. 487
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Figure 1. DE in Long-Standing T1D Is Characterized by Intestinal Mucosa Abnormalities and Impairment in CoSCs
(A–C) Bar graphs depict the score of diarrhea, abdominal pain, and constipation according to the administration of the GSRS questionnaire in healthy subjects
(CTRL) and long-standing T1D individuals (T1D+ESRD). Gray area indicates normal range for the parameter.
(D–F) Bar graphs report the measurements of anorectal sphincter contracting tone (mmHg), reflex response (ml), and urgency volume (ml) by anorectal
manometry in healthy subjects (CTRL) and long-standing T1D individuals (T1D+ESRD). Gray area indicates normal range for the parameter. n = 20 CTRL and
n = 60 T1D+ESRD individuals were included in the evaluation.
(G1, G2, I1, I2, K1, K2, M1, M2, O1, O2, Q1, and Q2) Representative images of H&E histology staining, immunoreactive MKI67+ cells (MIB1+), ultrastructural
analysis of neural structures with red arrows indicating localization and presence of neuroendocrine vesicles, immunohistochemical expression of 5-HT,
aldehyde dehydrogenase (Aldh)+ cells, and EphB2+ expression on bioptic samples obtained from healthy subjects (CTRL; G1, I1, K1, M1, O1, and Q1) and long-
standing T1D individuals (T1D+ESRD; G2, I2, K2, M2, O2, and Q2). Ultrastructural analysis scale bar, 2,000 nm. Original histology magnification: 1003 in (G1) and
(G2); 4003 in (I1), (I2), (K1), and (K2); 403 in (O1) and (O2); 2003 in (Q1) and (Q2). Scale bar, 80 mm.
(H, J, L, N, P, and R) Bar graphs reporting the measurement of crypts, the number of MKI67+ (MIB1+) cells, the number of neuroendocrine vesicles of nerve
terminals (number of cases with >3 NE vesicles detected per nerve terminal), the number of 5-HT+ and Aldh+ cells, and the of EphB2+ expression (intensity score
0–5) in CTRL and long-standing T1D subjects (T1D+ESRD). n = 20CTRL and n = 60 T1D+ESRD individuals were included in the evaluation. Data are expressed as
mean ± SEM unless differently reported. *p < 0.01; **p < 0.001; ***p < 0.0001.
GSRS, Gastrointestinal Symptom Rating Scale; T1D, type 1 diabetes; ESRD, end stage renal disease; CTRL, healthy subjects; MIB1, antibody against MKI67;
EphB2, Ephrin B receptor 2; Aldh, aldehyde dehydrogenase; 5-HT, serotonin; NE, neuroendocrine vesicles.high glucose (Figure 3D). Finally, serum levels of free IGF-I ap-
peared significantly reduced in long-standing T1D as compared
to healthy subjects (Figure 3E), indicating that circulating IGF-I
and IGFBP3 levels are altered in long-standing T1D.
Peripheral IGFBP3 and IGF-I Control CoSCs
To further elucidate the role of circulating IGF-I and IGFBP3 in
the regulation of the CoSCs and of intestinal epithelial prolifera-
tion, we demonstrated the expression of IGF-I receptor (IGF-IR)
and of IGFBP3 receptor (TMEM219) on isolated crypts (Figures
3F–3H; Figures S1M–S1N) using RT-PCR and WB, and we
confirmed the expression of IGF-IR on CoSCs with immuno-488 Cell Stem Cell 17, 486–498, October 1, 2015 ª2015 Elsevier Inc.staining (Figures S1N1 and S1N2) and that of TMEM219 with
in situ hybridization (Figures 3G1 and 3G2). In order tomechanis-
tically confirm the role of IGF-I and IGFBP3 on CoSCs, we tested
the effect of several molecules, identified by proteomic profiling,
in our in vitro mini-gut assay. Our strategy to select potential tar-
gets is reported in the Supplemental Information. The severely
altered mini-guts generated from intestinal samples obtained
from T1D+ESRD individuals were rescued by the addition of re-
combinant human IGF-I (IGF-I) to the culture medium (Figure 3I),
while the addition of recombinant human IGFBP3 (IGFBP3) re-
sulted in the abrogation of the positive effect observed with
IGF-I, with a decreased development of mini-guts and increased
Figure 2. DE in Long-Standing T1D Is Associated with a Defect in CoSCs
(A and B) Representative flow dot plots of EphB2low, EphB2medium, and EphB2hi cells in healthy subjects (CTRL) and long-standing T1D individuals (T1D+ESRD).
(C–E) Bar graphs depict results of flow cytometric analysis of EphB2hi+, EphB2hi+LGR5+, and EphB2+h-TERT+ cells in freshly isolated crypts (n = 10 CTRL and
n = 10 T1D+ESRD).
(F–H) Bar graphs depict expression data of CoSC markers EphB2, LGR5, and h-TERT as normalized mRNA expression measured by RT-PCR on isolated
intestinal crypts. All samples were run in triplicate and normalized to expression of the housekeeping gene ACTB (DDCt).
(I) Scatter plot represents the CoSC signature markers and stem cell transcriptome profiling examined in freshly isolated intestinal crypts of n = 10 healthy
subjects (CTRL) and n = 10 long-standing T1D individuals (T1D+ESRD).
(J1 and J2) Representative images of mini-guts cultured for 8 days in vitro obtained from previously isolated crypts of long-standing T1D individuals (T1D+ESRD)
and healthy subjects (CTRL). 103 magnification. Scale bar, 50 mm.
(K) Bar graph depicts the percentage of developed mini-guts of the total at 8 days of culture of freshly isolated intestinal crypts from n = 10 CTRL and n = 10
T1D+ESRD individuals.
(L1–L4) Representative images ofmini-guts obtained frompreviously isolated crypts of healthy subjects (CTRL) and cultured for 8 days in the following conditions:
L1 = normal (FBS) serum+normal glucose (5 mM); L2 = T1D+ESRD serum+normal glucose; L3 = normal serum+high glucose (35 mM); L4 = T1D+ESRD
serum+high glucose. 103 magnification. Scale bar, 50 mm.
(M) Bar graph grouping percentage of developed mini-guts of the total at 8 days of culture from freshly isolated intestinal crypts cultured with the following
conditions: normal (FBS) serum+normal glucose (5 mM); T1D+ESRD serum+normal glucose; normal serum+high glucose (35 mM); T1D+ESRD serum+high
glucose. Statistical significance has been calculated within each group (normal glucose+normal serum, medium+high glucose, medium+long-standing T1D
serum, and high glucose+long-standing T1D serum) by comparing different culturing conditions. Comparison in the bar graph refers to all conditions versus
normal serum+normal glucose.
(N) Transcriptome profiling depicting CoSC-signaturemarker expression in isolated crypts obtained from healthy subjects and cultured with/without high glucose
and/or long-standing T1D serum. n = 10 subjects per groupwere evaluated. Data are expressed asmean ± SEMunless differently reported. *p < 0.01; **p < 0.001;
***p < 0.0001. See also Figure S1.
CoSC, colonic stem cell; T1D, type 1 diabetes; ESRD, end stage renal disease; CTRL, healthy subjects; EphB2, Ephrin B receptor 2; LGR5, leucine-rich repeat
containing G protein-coupled receptor 5; RT-PCR, real-time polymerase chain reaction; ACTB, beta actin; FBS, fetal bovine serum.
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Figure 3. Circulating IGF-I and IGFBP3 Are Altered in Long-Standing T1D and Its Manipulation in Vitro Induces Profound Effects on CoSC
Growth and Self-Renewal
(A) Heat map represents the proteomic profile in long-standing T1D (T1D+ESRD) as compared to healthy subjects (CTRL). The complete dataset of identified and
quantified proteins was subjected to statistical analysis (p < 0.01). Significantly differentially expressed proteins were further analyzed through hierarchical
clustering. Sera of n = 10 CTRL and n = 10 T1D+ESRD individuals were analyzed.
(B) Bar graph depicts LFQ intensity for a single protein extrapolated from the untargeted proteomic analysis, insulin-like growth factor binding protein 3 (IGFBP3).
(C1 and C2) Representative images (403magnification) of IGFBP3 expression in the liver. IGFBP3 is mildly and diffusely expressed in the liver parenchyma from
healthy subjects (C1), while it is more zonally positive in long-standing diabetic individuals (C2).
(D) Bar graph represents IGFBP3 levels measured by ELISA in the supernatants of immortalized human hepatoma cell line (HuH-7) cultured for 5 days at different
glucose concentrations (35 mM: high glucose; 20 mM: intermediate glucose; 5 mM: normal glucose). Experiments were performed in triplicate.
(E) Bar graph represents insulin-like growth factor 1 (IGF-I) levels measured by ELISA in serum of healthy subjects and long-standing T1D (T1D+ESRD).
(F) WB analysis (cropped blots) confirmed IGF-IR and TMEM219 expression on the intestinal crypt surface. Evaluation of total IGF-IR expression by WB includes
the detection of IGF-IRa, a subunit of IGF-IR whole protein.
(G1 andG2) Representative pictures of TMEM219 in situ hybridization (G1, negative control; G2, TMEM219 staining) performed on rectal mucosa biopsy samples
obtained from CTRL. 203 magnification.
(H) Bar graph depicts normalized mRNA expression of TMEM219 (IGFBP3 receptor) using the DDCt method. n = 5 subjects per group were evaluated.
(I) Bar graph grouping percentage of developedmini-guts of the total obtained from long-standing T1D individuals in different conditions and showing the effect of
IGF-I, IGFBP3, and anti-IGF-IR. The p values are relative to baseline conditions and addition of IGF-I to culture.
(J) Bar graph representing normalized mRNA expression of caspase 8 and caspase 9 in crypts isolated from healthy subjects cultured in the presence of IGFBP3
and IGF-I+IGFBP3. Experiments were performed in triplicate.
(K) Bar graph grouping percentages of developedmini-guts of the total at 8 days of culture, obtained from healthy subjects and cultured in the presence of a pan-
caspase inhibitor or selective inhibitors of caspases 8, 9, and 3 and IGFBP3. Assay was performed in triplicate.
(L) Bar graphs grouping percentages of developed mini-guts of the total obtained from healthy subjects and cultured in different conditions (normal
glucose+normal serum, high glucose+normal serum, T1D+ESRD serum+normal glucose, and T1D+ESRD serum+high glucose) and showing the effects of IGF-I,
IGFBP3, and anti-IGF-IR. The p values are relative to the baseline condition (medium alone, medium+high glucose, medium+long-standing T1D serum, and high
(legend continued on next page)
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formation of collapsed and distorted organoids (Figure 3I).
Because IGFBP3 has been recently shown to act independently
of IGF-I (Williams et al., 2007) via the IGFBP3 receptor
(TMEM219) (Baxter, 2013), it was necessary to clarify whether
IGFBP3 exerts its effects on CoSCs by binding IGF-I or by
directly targeting TMEM219 on CoSCs. We first confirmed that
IGFBP3 has a direct pro-apoptotic effect on CoSCs by demon-
strating increased caspse 8 and caspse 9 expression in mini-
guts obtained from healthy subjects and long-standing T1D indi-
viduals and cultured with IGFBP3 (Figure 3J; Figures S2A and
S2B), while the addition of a pan-caspase inhibitor (Z-VAD-
FMK) or both selective inhibitors of caspases 8 and 9, but not
the addition of caspase 3 inhibitor, abrogated the IGFBP3 effect
(Figure 3K). We then demonstrated that the addition of IGF-I did
not rescue the development of mini-guts obtained from healthy
subjects and exposed to IGFBP3 (Figure 3L), confirming that
IGFBP3 may act through both a direct and an indirect IGF-I
mechanism. Interestingly, high glucose alone was unable to
completely disrupt mini-gut growth, and anti-IGF-IR did not
worsen growth and morphology of mini-guts formed from
healthy subjects (Figure 3L). The addition of IGF-I to mini-guts
generated from healthy subjects, but cultured with high glucose
and serum from long-standing T1D individuals, rescuedmini-gut
morphology, while IGFBP3 abolished the positive effect of IGF-I
when added to the mini-gut culture (Figure 3L). Interestingly,
the use of healthy subjects’ ‘‘CTRL’’ serum in culturing crypts
obtained from long-standing T1D nearly restoredmini-gut devel-
opment/morphology, indicating that circulating factors, and in
particular the IGF-I/IGFBP3 dyad, control CoSCs (Figures S2C
and S2D). We then genetically modulated TMEM219 expression
by using siRNA in vitro in mini-guts obtained from healthy sub-
jects. Knockdown of TMEM219 in mini-guts preserved their
ability to grow and self-renew, despite the addition of IGFBP3
and high glucose with long-standing T1D serum (Figure 3M).
Concomitant blockade of TMEM219 by siRNA and antibody
blockade of IGF-IR did not result in any additional beneficial ef-
fect on mini-gut development despite our using serum from
healthy subjects or from long-standing T1D (Figure S2E).
Other circulating proteins that appeared altered in the serum
proteome of long-standing T1D individuals were tested in the
in vitro mini-gut assay and did not show any significant effect
on mini-gut growth (Figures S2F and S2G). C-peptide and insu-
lin, which are commonly altered in T1D and which may interfere
with the IGF-I/IGFBP3 dyad by binding IGF-IR (Figures S2F–
S2H), were tested as well and did not show any effect.
To further confirm that the IGF-I/IGFBP3 dyad effectively
targets CoSCs and not only crypts, we tested the effect of
IGF-I/IGFBP3 on single-cell-derived mini-guts. We flow-sorted
EphB2+ cells from isolated crypts and established that
TMEM219 was highly expressed on their surface (Figure 4A).glucose+long-standing T1D serum). Additional p values have been calculated t
medium alone versus medium+high glucose versus medium+high glucose+long
(M) Bar graph grouping percentages of developed mini-guts of the total obtained
with siRNA, compared to TMEM219-expressing crypts in medium alone and in
triplicate. Data are expressed as mean ± SEM unless differently reported. *p < 0
IGF-I, insulin-like growth factor 1; IGFBP3, insulin-like growth factor binding prote
type 1 diabetes; ESRD, end stage renal disease; CTRL, healthy subjects; RT-P
quantitation; SEM, standard error of the mean; siRNA, small RNA interference; in
CeWe then cultured EphB2+ cells in the in vitro single-cell-derived
mini-gut assay and confirmed that high glucose and long-
standing T1D serum exposure as well as the addition of IGFBP3
significantly abrogated single-cell-derived mini-gut growth, thus
recapitulating the primary features reported in our previous
observations on crypt-derived mini-guts (Figure 4B, Figures
S3A1–S3A3). Moreover, expression of caspase 8 and caspase 9
was upregulated in IGFBP3-treated mini-guts and in those
exposed to high glucose and long-standing T1D serum, while
MKI67, a marker of proliferation, was significantly underex-
pressed (Figures S3B–S3D).
Effect of the IGF-I/IGFBP3 Dyad on Previously Known
Pathways that Control CoSCs
In order to clarify the effects of the IGF-I/IGFBP3 dyad on path-
ways previously known to be involved in CoSC niche function
(i.e., Wnt/Notch/BMP), we obtained from our stem cell transcrip-
tome profile the expression of niche-regulating specific gene
transcripts. IGF-I restores the expression of some factors
associated with Wnt/Notch signaling pathways on mini-guts
obtained from crypts of T1D+ESRD (Figure S3E, Table S2), while
IGFBP3 poorly affects Wnt/Notch/BMP gene expression in
mini-guts obtained from crypts of healthy subjects or from those
obtained from T1D+ESRD individuals (Figure S3F, Table S2).
This confirms that IGF-I preserves the expression of some genes
involved in Wnt/Notch/BMP signaling, but also that IGFBP3
acts independently on CoSCs, without major alterations in the
expression of key target genes of the other previously known
pathways.
Effect of the IGF-I/IGFBP3 Dyad on Apoptotic Pathways
An extensive transcriptome analysis performed to clarify the
IGFBP3 caspase-mediated effect on mini-guts (Figures 4C and
4D; Figures S3G and S3H, Table S3) showed that the addition
of IGFBP3 to mini-guts grown from healthy subject crypts was
associated with a significant upregulation of caspase cascade
activators (caspase 8 and caspase 9) and pro-apoptotic genes,
while the anti-apoptotic gene BCL2 was downregulated (Fig-
ure 4C). Interestingly, anti-apoptotic genes (BCL2, FAS, and
NOL3) were significantly underexpressed in mini-guts grown
from T1D+ESRD crypts as well, as compared to healthy sub-
jects, while the majority of caspase-related genes (caspase 1,
5, 7, 8, 9, and 14) were overexpressed (Figure S3G). Moreover,
the expression of genes involved in other pro-apoptotic path-
ways was either not altered (i.e., FASL, FADD, and TNF) or in-
hibited (TRADD) in T1D+ESRD mini-guts. The opposite effect
was observed when IGF-I was added (Figure 4D; Figure S3H).
The absence of alterations in the expression of oxidative stress
target genes (data not shown), and the absence of any effect
of oxidative stress factors (Figures S3I and S3J), confirmedo compare the difference in mini-gut growth among the following conditions:
-standing T1D serum. Assay was performed in triplicate.
from healthy subjects, cultured for 8 days, and exposed to TMEM219 targeting
medium+high glucose+long-standing T1D serum. Assay was performed in
.01; **p < 0.001; ***p < 0.0001. See also Figures S1 and S2.
in 3; IGF-IR, insulin-like growth factor 1 receptor; CoSC, colonic stem cell; T1D,
CR, real-time polymerase chain reaction; ACTB, beta actin; LFQ, label-free
hib, inhibitor.
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Figure 4. Effects of the Peripheral IGF-I/IGFBP3 Dyad on Single-Cell-Derived In Vitro Mini-Guts and the caspase Cascade
Manipulating the peripheral IGF-I/IGFBP3 dyad alters the progression of diabetic enteropathy in a preclinical model of diabetic enteropathy, while the treatment of
long-standing T1D with simultaneous pancreas-kidney transplantation (SPK) ameliorates intestinal symptoms, motility, and morphology.
(A) Bar graph representing normalizedmRNA expression of TMEM219, LRP1, and TGF-b type I and II in EphB2+ sorted single cells obtained from crypts of healthy
subjects. Experiments were performed in triplicate.
(B) Bar graphs showing percentages of developed single-cell-derived mini-guts (of the total) obtained from EphB2+ cells sorted from freshly isolated crypts of
healthy subjects and cultured in different conditions (normal glucose+normal serum, high glucose+normal serum, T1D+ESRD serum+normal glucose, and
T1D+ESRD serum+high glucose) and showing the effect of IGF-I and IGFBP3. The p values are relative to baseline conditions.
(C and D) Scatter plot representing the apoptosis transcriptome profiling examined in freshly isolated intestinal crypts of healthy subjects (CTRL) and long-
standing T1D individuals (T1D+ESRD) cultured with/without IGFBP3 and IGF-I. Experiments were performed in triplicate.
(E–G) Line graphs reporting the number of crypts (E), depth of crypts (F), and width of crypts (G) assessed on intestinal lower tract sections harvested at baseline
and after 8 weeks from STZ-treated B6 mice developing DE (B6+STZ), naive B6 (B6), and naive B6 treated with IGFBP3 (B6+IGFBP3). STZ, streptozoticin-
treated. n = 3 mice per group were evaluated.
(H) Bar graph representing the number of Aldh+ cells/mm2 in immunostained sections of STZ-treated B6 mice developing DE, B6, and naive B6 treated with
IGFBP3 (B6+IGFBP3).
(I1–I6) Representative images of intestinal crypts on H&E sections of B6, B6+STZmice developing DE, and naive B6 treated with IGFBP3 (B6+IGFBP3). Histology
magnification, 2003 in (I1)–(I3) and 4003 in (I4)–(I6).
(J1–J3) Representative images of Aldh+ cells on immunostained sections of intestinal lower tract harvested from STZ-treated B6 mice developing DE, B6, and
naive B6 treated with IGFBP3 (B6+IGFBP3). Histology magnification, 4003.
(K) Schematic attempt to represent the effect of circulating IGF-I and IGFBP3 on CoSCs.
(L, N, and P) Bar graphs report themeasurement of MIB1+ and Aldh+ cells and EphB2+ expression (intensity score 0–5) in the four groups of subjects (n = 20CTRL,
n = 30 SPK, n = K+T1D, and n = 60 T1D+ESRD).
(M1, M2, O1, O2, Q1, and Q2) Representative images of MIB1+ and Aldh+ cells, and EphB2+ expression in immunostained rectal mucosa bioptic samples of
T1D+ESRDwho underwent kidney transplant alone (K+T1D) or SPK transplantation at 8 years of follow-up. Histology magnification, 4003 in (M1), (M2), (O1), and
(O2), 203 in (Q1) and (Q2). Scale bar, 80 mm. Data are expressed asmean ± SEMunless differently reported. *p < 0.01; **p < 0.001; ***p < 0.0001. See also Figures
S3, S4, and S5.
STZ, streptozoticin-treated; B6, C57BL/6J mice; IGF-I, insulin-like growth factor 1; IGFBP3, insulin-like growth factor binding protein 3; IGF-IR, insulin-like growth
factor 1 receptor; CoSC, colonic stem cell; T1D, type 1 diabetes; ESRD, end stage renal disease; CTRL, healthy subjects; SPK, simultaneous kidney-pancreas
transplantation; K+T1D, kidney transplantation alone in type 1 diabetes;MIB1, antibody againstMKI67; EphB2, Ephrin B receptor 2; Aldh, aldehyde dehydrogenase.
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Figure 5. Treatment of Long-Standing T1D with SPK Replenishes CoSCs and Restores the CoSC Signature Profile and Mini-Gut Develop-
ment through Restoration of Circulating IGF-I and IGFBP3
(A–C) Bar graphs depict results of flow cytometric analysis of EphB2hi+, EphB2hi+LGR5+, and EphB2+h-TERT+ cells obtained from isolated crypts in long-standing
T1D (Baseline) or T1D+ESRD who underwent kidney+pancreas (SPK) or kidney alone (K+T1D) transplantation at 8 years of follow-up. n = 10 subjects per group
were evaluated.
(D–F) Bar graphs depict normalized mRNA expression of intestinal stem cell markers EphB2, LGR5, and h-TERT measured by RT-PCR on isolated intestinal
crypts obtained from long-standing T1D (Baseline) or T1D+ESRD who underwent kidney+pancreas (SPK) or kidney alone (K+T1D) transplantation at 8 years of
(legend continued on next page)
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apoptotic-related caspase-mediated IGFBP3 activity. The ex-
pression of the survival factor beta-catenin (CTNNB1) was
reduced in mini-guts generated from crypts of T1D+ESRD
individuals as compared to those obtained from healthy subjects
(Figure S3K) and was increased by the addition of IGF-I
(Figure S3L), further supporting the concept of an apoptotic-
related mechanism, whereby circulating IGFBP3 directly con-
trols CoSCs (Movie S1).
Manipulation of the Circulating IGF-I/IGFBP3 Dyad
Alters the Course of Diabetic Enteropathy in a
Preclinical Model
In order to further demonstrate the relevance of IGF-I/IGFBP3
circulating factors in vivo, we tested the effects of IGF-I and
IGFBP3 administration in a preclinical model of DE. After
8 weeks of chemically induced diabetes (using streptozotocin
[STZ]), C57BL/6J (B6) mice showed a reduced number of
crypts in the colorectal tissue (Figure 4E), which displayed
increased depth (Figure 4F) and width in more than 70% of
cases (Figures 4G, 4I1, 4I2, 4I4, and 4I5) and a reduced number
of Aldh+ cells (Figures 4H–4J). Interestingly, these mice showed
increased serum levels of IGFBP3 and low levels of IGF-I, with
lower murine insulin levels as compared to naive B6 (Figures
S4A–S4C). Intraperitoneal (i.p.) administration of IGFBP3 in
naive B6 mice resulted in a reduction in local crypt numbers
(Figures 4E and 4I3), with the majority of crypts showing
increased depth and width (Figures 4F, 4G, 4I3, and 4I6) and
a significant reduction in Aldh+ cells as compared to those of
untreated mice (Figures 4H and 4J3). Those features were
aggravated by IGFBP3 administration to STZ-treated B6 mice
(Figures S4D–S4H), with evidence of decreases in weight (Fig-
ure S4I), CoSC loss (Figures S4J–S4L), and upregulated
expression of caspase 8 and 9 (Figures S4M and S4N). Admin-
istration of i.p. IGF-I in STZ-treated B6 mice only partially
improved mucosa morphology and increased the number of
crypts, which remained abnormal (Figure S4D, S4H1, and
S4H2), and only partially restored the number of Aldh+ cells
(Figure S4G). Validation for successful administration of the in-
jected compounds was performed by analysis of IGF-I/IGFBP3
peripheral levels 1 hr after their injection (Figures S4O and S4P).
These observations confirmed that the peripheral IGF-I/IGFBP3
dyad controls CoSCs (Figure 4K).follow-up. All samples were run in triplicate and normalized to expression of the ho
evaluated.
(G) WB analysis depicts the expression of EphB2, LGR5, and h-TERT in isolated
group were evaluated.
(H) Bar graph depicts the percentages of developedmini-guts of the total at 8 days
individuals (Baseline) or SPK and K+T1D subjects at 8 years of follow-up. n = 10
(I) Heatmap represents the CoSC signature marker transcriptomic profiling exam
(T1D+ESRD), SPK, and K+T1D subjects at 8 years of follow-up. n = 10 subjects
(J) Bar graph represents IGF-I levels measured by ELISA in serum of the four group
(K) Bar graph depicts IGFBP3 levels measured by ELISA in serum of the four gro
(L and M) Correlation between IGFBP3 serum levels and intestinal symptoms a
and SPK (M) group. Analysis was conducted using ANOVA (p < 0.05) in compari
*p < 0.01; **p < 0.001; ***p < 0.0001. See also Figures S5 and S6.
CoSC, colonic stem cell; T1D, type 1 diabetes; ESRD, end stage renal disease;
EphB2, Ephrin B receptor 2; LGR5, leucine-rich repeat containing G protein-coupl
K+T1D, kidney transplantation alone in type 1 diabetes; IGF-I, insulin-like growth
error of the mean.
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Pancreas-Kidney Transplantation Reverts Clinical
and Morphological Features of DE
The gold standard treatment for long-standing T1D is simulta-
neous pancreas-kidney transplantation (SPK), which affords
stable glycometabolic control, near-normalized risk factors,
and prolonged survival (Table S4) (Fiorina et al., 2004, 2005; Folli
et al., 2010; Secchi et al., 1998; Smets et al., 1999). However,
individuals with T1D+ESRD are also treated with kidney trans-
plantation alone but they remain diabetic (K+T1D) (Fiorina
et al., 2001). A significant improvement in gastrointestinal symp-
toms was evident over time after SPK in our cohort of trans-
planted individuals, while the K+T1D group did not report any
benefit (Figures S5A–S5C), suggesting that DE is reversible.
Treatment of Long-Standing T1D with SPK
Reestablishes Intestinal Mucosa Morphology
and Local Self-Renewal Properties
Analysis of intestinal mucosa samples showed a significant
recovery in the structure of the epithelial compartment, with
compensatory epithelial hyperplasia in the SPK group (Figures
S5D1 and S5D2). Recovery of normal crypt histology and
number was evident in the SPK group when long-standing T1D
was successfully treated while none of these features were
evident in individuals who received kidney transplant only and
remained diabetic (Figures S5D1 and S5D2). Epithelial cell prolif-
eration (MIB1+ cells) increased after SPK over time as compared
to baseline and K+T1D at each time point (Figures 4L–4M), with
near-normalization of intestinal morphology, epithelial renewal,
and neural features (Figures S5E–S5K). This demonstrates that
treatment of long-standing T1D with SPK promoted recovery
of intestinal epithelial repair and self-renewing properties.
Treatment of Long-Standing T1D Promotes Restoration
of CoSCs
Treatment of long-standing T1D with SPK is associated with an
increase in Aldh+ cells (Figures 4N–4O) and EphB2+ expression
in the intestinal crypt (Figures 4P–4Q) and nearly normalizes
the percentage of EphB2hi+, EphB2+h-TERT+, and EphB2hi+
LGR5+ cells in isolated intestinal crypts as compared to baseline
(Figures 5A–5C). CoSC marker expression (Figures 5D–5G) and
growth/morphology of mini-guts obtained from SPK individualsusekeeping geneACTB using theDDCtmethod. n = 10 subjects per groupwere
intestinal crypts of the four groups at 8 years of follow-up. n = 5 subjects per
of culture of freshly isolated intestinal crypts obtained from long-standing T1D
subjects per group were evaluated.
ined in freshly isolated intestinal crypts of CTRL, long-standing T1D individuals
per group were evaluated.
s of subjects at 8 years of follow-up. n = 10 subjects per group were evaluated.
ups of subjects. n = 20 subjects per group were evaluated.
ssessed using the GSRS questionnaire (0–7) in n = 20 subjects of K+T1D (L)
ng all groups. Data are expressed as mean ± SEM unless differently reported.
CTRL, healthy subjects; SPK, simultaneous kidney-pancreas transplantation;
ed receptor 5; RT-PCR, real-time polymerase chain reaction; ACTB, beta actin;
factor 1; IGFBP3, insulin-like growth factor binding protein 3; SEM, standard
were nearly normalized as well (Figure 5H, Figures S6A1–S6A6).
Transcriptome analysis revealed that SPK nearly restored the
expression of CoSCs markers and pathways involved in preser-
ving CoSCs integrity (Figure 5I, Figure S6B). Taken together, our
data suggest that treatment of long-standing T1D with SPK pro-
motes restoration of CoSCs.
Treatment of Long-Standing T1D with SPK Restores
Circulating IGF-I and IGFBP3
Broad proteomic analysis and targeted immunoassay revealed
a near-normalization of IGFBP3 and IGF-I serum levels after
SPK (Figures 5J and 5K) in association with a nearly reestab-
lished expression of IGF-IR (Figure S6C). These results were
not evident in the K+T1D group, who showed low levels of
IGF-I (Figure 5J) and IGF-IR expression (Figure S6C) and only
a partial recovery in their IGFBP profile (Figure S6D). A signifi-
cant correlation between IGFBP3 serum levels and intestinal
symptoms in both SPK and K+T1D groups, but more evident
in the latter, confirmed that the restoration of IGFBP3 levels is
associated with an improvement in DE (Figures 5L and 5M).
Treatment of long-standing T1D with SPK ameliorates DE
via a glucose-associated restoration of the circulating IGF-I/
IGFBP3 dyad.
The Ecto-TMEM219 Recombinant Protein Abrogates
IGFBP3-Mediated Mini-Gut Destruction In Vitro and
Preserves CoSCs In Vivo in a Murine Model of DE
In order to further demonstrate the IGFBP3-mediated detri-
mental effects on CoSCs, we generated a recombinant protein
based on the 161-amino-acid TMEM219 extracellular domain
(ecto-TMEM219) with >90% purity. Addition of ecto-TMEM219
(2:1 molar ratio with IGFBP3) to crypts obtained from CTRL
and cultured with IGFBP3 abrogated the pro-apoptotic effect
of IGFBP3 on mini-guts and preserved the regenerative proper-
ties of crypts to generate mini-guts (Figure 6A). The expression
of the CoSC marker EphB2 was significantly recovered in mini-
guts cultured with IGFBP3 and ecto-TMEM219 (Figure 6B),
emphasizing a favorable effect in preserving CoSCs, which
was also confirmed in high-glucose-cultured mini-guts (Fig-
ure 6A). Moreover, analysis of caspase 8 and 9 by RT-PCR
documented a net decrease in their expression when ecto-
TMEM219 was added to IGFBP3-cultured mini-guts as
compared to IGFBP3 alone (Figures 6C and 6D). We then
treated STZ-B6 mice with ecto-TMEM219 and observed
improved mucosa morphology with recovered number, depth,
and width of crypts (Figures 6E and 6G). Administration of
ecto-TMEM219 was associated with an increase in mouse
body weight as compared to STZ-treated B6 (Figure 6H), with
significant regain of CoSCs (Figures 6I–6K), a decreased
expression of caspase 8 and 9 (Figures 6L and 6M), and a
reestablishment of circulating IGFBP3 levels (Figure 6N), there-
fore suggesting a curative potential of ecto-TMEM219 in a
therapeutic scenario.
DISCUSSION
DE represents a clinically relevant complication in individuals
with T1D, as it is associated with lower quality of life, malnutri-
tion, and malabsorbtion (Bytzer et al., 2002; Faraj et al., 2007;CeTalley et al., 2001). Particularly, in individuals with long-stand-
ing T1D (T1D+ESRD), intestinal disorders occur with high
frequency and severity (Cano et al., 2007; Wu et al., 2004), re-
sulting in body mass loss and cachexia (Pupim et al., 2005),
indicating that enteropathy is an important complication of
long-standing T1D (Atkinson et al., 2014; Pambianco et al.,
2006). Our results demonstrate that individuals with long-
standing T1D experienced severe intestinal disorders and that
these clinical conditions are associated with alterations of the
intestinal mucosa, with reduced proliferation of intestinal
epithelial cells and with signs of neural degeneration. Similar
features have also been reported in rodent models of T1D
and DE (Dome`nech et al., 2011). Our data link DE to a defect
in CoSCs and implicate IGFBP3 as having an important role
in the maintenance of intestinal epithelium homeostasis. While
hyperglycemia is a prominent feature of T1D, our in vitro
studies suggest that this feature cannot fully explain DE and
that circulating factors may play an important role. Proteomic
analysis led to the identification of IGF-I as an enterotrophic
factor involved in the homeostasis of CoSCs. We then
confirmed that IGF-I and IGFBP3 control CoSCs and that this
axis is dysfunctional in long-standing T1D. Our data indicate
that IGF-I acts as a circulating enterotrophic factor that pro-
motes crypt growth and controls CoSCs through IGF-IR, while
IGFBP3 can block IGF-I signaling by binding circulating IGF-I
and reducing its bioavailability. In addition, and most impor-
tantly, we showed that IGFBP3 acts through a pro-apoptotic
IGF-I-independent mechanism on CoSCs, which we demon-
strated express TMEM219 (the IGFBP3 receptor), thereby
inducing the failure of mini-gut growth. This latter effect is
caspase 8 and 9 mediated and TMEM219 dependent; indeed,
the absence of the IGFBP3 receptor (TMEM219) on CoSCs
greatly diminished high-glucose-associated CoSC injuries.
T1D together with starvation and cachexia are characterized
by low circulating IGF-I levels (Bondy et al., 1994; Giustina
et al., 2015) due to reduced hepatic IGF-I release, which is
controlled and stimulated by endogenous insulin (Le Roith,
1997; Sridhar and Goodwin, 2009). More importantly, hypergly-
cemia appeared to have a direct effect on hepatic synthesis
and release of IGFBP3. IGFBP3 may thus act as a hepatic
hormone that reduces intestinal absorptive capacity during
hyperglycemia. Interestingly, SPK provided a proof of concept
to our hypothesis and supported our findings regarding the ex-
istence of circulating factors that control CoSCs. The striking
improvement of clinical and functional features of DE that
we observed in our study, associated with replenishment of
CoSCs and with restoration of the circulating IGF-I and
IGFBP3, strengthens our hypothesis. Finally, the newly gener-
ated ecto-TMEM219 recombinant protein improved DE in dia-
betic mice in vivo and restored the ability of mini-guts to
grow normally in vitro, thus confirming the role of IGFBP3 in
controlling CoSCs and paving the way for a potential therapeu-
tic strategy (Movie S1). In summary, our study shows that an
IGFBP3-mediated disruption of CoSCs linked to hyperglycemia
is evident in DE. We suggest that circulating IGF-I/IGFBP3
represents a hormonal dyad that controls CoSCs and a thera-
peutic target for individuals with intestinal disorders caused by
diabetes mellitus of long duration (Bondy et al., 1994; Bortvedt
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Figure 6. Treatmentwith theNewlyGeneratedRecombinant Protein Ecto-TMEM219 (Ecto-TMEM219) Abrogates IGFBP3-MediatedMini-Gut
Destruction and Preserves CoSCs in a Preclinical Model
(A) Bar graph grouping percentages of developed mini-guts of the total obtained from healthy subjects in different conditions and showing the effect of ecto-
TMEM219 at various concentrations (1:2, 1:1, and 2:1molar ratio as compared to IGFBP3) in IGFBP3-treatedmini-guts and in those exposed to high glucose. The
p values are relative to baseline conditions.
(B) Bar graph representing normalized mRNA expression of EphB2 in crypts isolated from healthy subjects cultured in the presence of IGFBP3 and ecto-
TMEM219+IGFBP3. Experiments were performed in triplicate.
(C and D) Bar graphs representing normalized mRNA expression of caspases 8 and 9 in crypts isolated from healthy subjects cultured in the presence of IGFBP3
and ecto-TMEM219+IGFBP3. Experiments were performed in triplicate.
(E–G) Line graphs reporting the number of crypts (E), depth of crypts (F), and width of crypts (G) assessed on intestinal lower tract sections harvested at baseline
and after 8 weeks from STZ-treated B6mice developing DE (B6+STZ), naive B6 (B6), and STZ-B6mice treated with ecto-TMEM219. STZ, streptozoticin-treated.
n = 3 mice per group were evaluated.
(H) Line graph reporting the weight at baseline and after 8 weeks of STZ-treated B6 mice developing DE (B6+STZ), naive B6 (B6), and STZ-treated B6 mice
developing DE treated with ecto-TMEM219. STZ, streptozoticin-treated. n = 3 mice per group were evaluated.
(I) Bar graph representing results of flow cytometric analysis of EphB2+ cells isolated from intestinal samples collected from naive B6 mice, STZ-treated B6 mice,
and STZ-B6 mice treated with ecto-TMEM219 at 8 weeks.
(J) Representative flow histograms of EphB2+ cells isolated from crypts isolated from naive B6 mice, STZ-treated B6 mice, and STZ-B6 mice treated with ecto-
TMEM219 at 8 weeks. n = 3–5 mice per group were evaluated.
(K) Bar graph representing normalized mRNA expression of Ephb2 in intestinal samples collected from naive B6 mice, STZ-treated B6 mice, and STZ-B6 mice
treated with ecto-TMEM219 at 8 weeks.
(L andM) Bar graph representing normalizedmRNA expression of caspase 8 (L) and caspase 9 (M) in intestinal samples collected from naive B6mice, STZ-treated
B6 mice, and STZ-B6 mice treated with ecto-TMEM219 at 8 weeks.
(N) Line graph representing murine IGFBP3 circulating levels measured in naive B6 mice (B6), STZ-treated B6 mice (B6+STZ), and B6+STZ mice treated
with ecto-TMEM219 at baseline and after 8 weeks. n = 3–5 mice per group. Data are expressed as mean ± SEM unless differently reported. *p < 0.01; **p < 0.001;
***p < 0.0001. See also Figure S6.
STZ, streptozoticin-treated;B6,C57BL/6Jmice; IGF-I, insulin-like growth factor 1; IGFBP3, insulin-like growth factor bindingprotein 3;CoSC,colonic stemcell; EphB2,
Ephrin B receptor 2; T1D, type 1 diabetes; ESRD, end stage renal disease; CTRL, healthy subjects; RT-PCR, real-time polymerase chain reaction; ACTB, beta actin.
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EXPERIMENTAL PROCEDURES
60 individuals with long-standing T1D (T1D+ESRD) registered on the waiting
list for SPK were enrolled in the study and compared with 20 healthy subjects
matched for age and gender (CTRL). Assessment of gastrointestinal symp-
toms, intestinal motility, and intestinal mucosa pathology defined DE. CoSCs
were identified on colonic purified crypts based on the expression of CoSC-
specific markers (flow cytometry, RT-PCR, WB, transcriptome profiling).
CoSC self-renewal properties were assessed by evaluation of the percentage
of in vitro developed mini-guts and by the characterization of their expression
of cell lineage markers in different conditions (Figures S6E–S6I and S6J). Inter-
ventional studies included the use of recombinant human IGF-I, recombinant
human IGFBP3, and anti-IGF-IR in vitro in mini-gut assay and in vivo in murine
models of DE. Animal studies were conducted on B6 mice purchased from
the Jackson Laboratory, in accordance with institutional guidelines (Harvard
Medical School Institutional Animal Care and Use Committee). Mice were
rendered diabetic with STZ injection and development of DE was assessed
after 8 weeks (via intestinal pathology, CoSCs flow cytometry, and RT-PCR).
The recombinant protein ecto-TMEM219 for in vitro and in vivo studies
(161 amino acids, 18.2 kDa) was generated using E. coli for expression and
synthesis, while purity was tested by SDS-PAGE and WB (Figures S6K and
S6L). The co-injection of IGFBP3 and ecto-TMEM219 prevented the increase
of IGFBP3 peripheral levels and implies the binding of ecto-TMEM219 with
IGFBP3 (Figure S6M). Broad serum proteomic analysis was used to detect
circulating factors that may regulate CoSCs and candidate factors were
then tested in the in vitro mini-gut assay (Table S5). Peripheral levels of IGF-I
and IGFBP3 were confirmed in human and murine studies using targeted
immunoassays. Detailed methods and statistical analysis are described in
the Supplemental Information. The study was approved by the Institutional
Review Board of Istituto di Ricovero e Cura a Carattere Scientifico Ospedale
San Raffaele, Milano, Italy (Enteropathy-Pancreas KidneyTransplantation/01
Secchi/Fiorina).
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